期刊
BRITISH JOURNAL OF CANCER
卷 100, 期 1, 页码 13-18出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6604822
关键词
hormone refractory prostate cancer; xenografts; novel therapeutics; PSA biomarker
类别
With docetaxel as effective chemotherapy for hormone refractory prostate cancer (HRPC), the number of new treatment combinations for HRPC is expanding demanding a fast-track screening system. This review elaborates on the use of xenograft models to select the most promising combination therapies for entering into phase II clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据